U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06926933) titled 'Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty' on April 08.
Brief Summary: This study is a multicenter, open-label, single-group, and phase 4 study to evaluate the efficacy and safety of 45 mg of leuprolide acetate in CPP.
Screening tests are performed after the subject agrees in writing to participate in the clinical trial, and subjects who meet the inclusion criteria and do not fall under the exclusion criteria are enrolled in the study. The target patients in this study are pediatric patients who have been diagnosed with CPP but have not yet received GnRH agonist treatment, and all ...